3.1.6 Excitotoxic injury (high calcium permeability of NMDARs) CIRI leads to excitotoxic injury, primarily due to the excessive release of excitatory amino acids
For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog
By understanding potential risks and precautions, you can make informed decisions about its use
Supplementing can help bridge the gap, but the speed at which you feel a difference depends heavily on how well your body absorbs the supplement